Skip to main content
Premium Trial:

Request an Annual Quote

Novartis Takes Equity Stake in Somalogic as Firms Extend Research Pact

NEW YORK (GenomeWeb) – Somalogic said today that Novartis has extended its multi-year research agreement covering the use of Somalogic's aptamer-based proteomics platform for drug development work.

Under the extended agreement, the two companies will continue efforts begun under an initial 2011 agreement to build a proprietary version of Somalogic's SomaScan proteomics assay and develop novel Somamer binding reagents for preclinical and clinical applications in Novartis's portfolio.

Novartis will also take an equity stake in Somalogic as part of the agreement.

"Our ongoing relationship with Novartis is a model for how we seek to develop strong scientific collaborations that drive new discoveries and build value for both parties," Somalogic CEO Byron Hewett said in a statement.

Financial and other terms of the deal were not disclosed.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.